Richard S. Lemons
No Rating Available
(Learn About Our Rating System)

Richard S. Lemons, MD, PhD

Languages spoken: English

Clinical Locations

Primary Location

Primary Children's Hospital

Pediatric Hematology/Oncology
100 N Mario Capecchi Drive
Salt Lake City , UT 84113
801-662-4700
Get Directions

Richard Lemons, MD, PhD, is a professor in the Department of Pediatrics at the University of Utah School of Medicine, medical director and chief of pediatric hematology/oncology at Primary Children's Medical Center and the University of Utah, and a Huntsman Cancer Institute investigator. He is involved in various clinical trials for pediatric malignancies and pediatric hematologic disorders.

Lemons earned a medical degree from George Washington University School of Medicine, Washington, DC; and performed an internship and residency at Johns Hopkins Hospital, Baltimore. Lemons was a staff member at St. Jude Children's Research Hospital prior to joining the University of Utah Department of Pediatrics. He is board certified in Pediatrics and Pediatric Hematology-Oncology.

Specialties

Richard Lemons, MD, PhD, is a professor in the Department of Pediatrics at the University of Utah School of Medicine, medical director and chief of pediatric hematology/oncology at Primary Children's Medical Center and the University of Utah, and a Huntsman Cancer Institute investigator. He is involved in various clinical trials for pediatric malignancies and pediatric hematologic disorders.

Lemons earned a medical degree from George Washington University School of Medicine, Washington, DC; and performed an internship and residency at Johns Hopkins Hospital, Baltimore. Lemons was a staff member at St. Jude Children's Research Hospital prior to joining the University of Utah Department of Pediatrics. He is board certified in Pediatrics and Pediatric Hematology-Oncology.

Board Certification and Academic Information

Academic Departments Pediatrics -Professor
Academic Divisions Hematology/Oncology

Education history

Undergraduate University of Connecticut B.A.
Doctoral Training Chemistry - Pennsylvania State University Ph.D.
Postdoctoral Fellowship Genetics - National Institutes of Health Postdoctoral Fellow
Professional Medical Medicine - George Washington University M.D.
Fellowship Cancer Bio Research - National Institutes of Health Fellow
Residency Pediatrics - Johns Hopkins Hospital Resident
Fellowship NRSA Tumor Cell Biology - St. Jude Children's Research Hospital Fellow
Certification Conflict Mediation - University of Utah Postgraduate Certificate

Selected Publications

Journal Article

  1. O'Connell N, van der Valk P, Le Quellec S, Gomez E, Monahan PE, Crary SE, Coppens M, Lemons R, Castaman G, Klamroth R, Symington E, Quon DV, Kampmann (2025). Invasive procedures and surgery following etranacogene dezaparvovec gene therapy in people with hemophilia B. Journal of thrombosis and haemostasis, 23(1), 73-84.
  2. Lemons R, Wang M, Curtin J, Lepatan LM, Male C, Peyvandi F, von Depka Prondzinski M, Wang R, McKeand W, Seifert W, Oldenburg (2024). Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B. TH open, 8(1), e155-e163.
  3. Constance JE, McFarland MM, Casucci T, Deininger MW, Enioutina EY, Job K, Lemons RS, Lim CS, Ward RM, Yellepeddi V, Watt K (2023). Mapping the Evidence for Opioid-Mediated Changes in Malignancy and Chemotherapeutic Efficacy: Protocol for a Scoping Review. JMIR research protocols, 12, e38167.
  4. Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, Lattimore S, Peerlinck K, Van der Valk P, Coppens M, Kampmann P, Meijer K, O'Connell N, Pasi KJ, Hart DP, Kazmi R, Astermark J, Hermans CRJR, Klamroth R, Lemons R, Visweshwar N, von Drygalski A, Young G, Crary SE, Escobar M, Gomez E, Kruse-Jarres R, Quon DV, Symington E, Wang M, Wheeler AP, Gut R, Liu YP, Dolmetsch RE, Cooper DL, Li Y, Goldstein B, Monahan P (2023). Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. The New England journal of medicine, 388(8), 706-718.
  5. Biltaji E, Enioutina EY, Yellepeddi V, Rower JE, Sherwin CMT, Ward RM, Lemons RS, Constance J (2020). Supportive care medications coinciding with chemotherapy among children with hematologic malignancy. Leukemia & lymphoma, 61, 1-12.
  6. Olson J, Mehra S, Hersh AL, Thorell EA, Stoddard GJ, Maese L, Barnette PE, Lemons RS, Pavia AT, Knackstedt E (2020). Oral Step-Down Therapy With Levofloxacin for Febrile Neutropenia in Children With Cancer. Journal of the Pediatric Infectious Diseases Society, 10(1), 27-33.
  7. Kaul S, Korgenski EK, Ying J, Ng CF, Smits-Seemann RR, Nelson RE, Andrews S, Raetz E, Fluchel M, Lemons R, Kirchhoff A (2016). A retrospective analysis of treatment-related hospitalization costs of pediatric, adolescent, and young adult acute lymphoblastic leukemia. Cancer medicine, 5(2), 221-9.
  8. Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey C (2015). Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet (London, England), 386(10004), 1649-58.
  9. Lowichik A, Zhou H, Pysher TJ, Smith L, Lemons R, Coffin C (2000). Therapy associated changes in childhood tumors. Advances in anatomic pathology, 7(6), 341-59.
  10. Morgan R, Riske CB, Meloni A, Ries CA, Johnson CH, Lemons RS, Sandberg A (1991). t(16;21)(p11.2;q22): a recurrent primary rearrangement in ANLL. Cancer genetics and cytogenetics, 53(1), 83-90.